What Is Happening to India s COVID-19 Vaccine Program? - Carnegie India - Carnegie Endowment for International Peace carnegieindia.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from carnegieindia.org Daily Mail and Mail on Sunday newspapers.
Modi-BoJo virtual summit: SII to make vaccine in Britain
New Delhi
Pune-based Serum Institute of Indiaâs plans to manufacture vaccines in the UK was conveyed to PM Modi by none other than the his British counterpart Boris Johnson at the India-UK virtual summit on Tuesday.
Headed by chief executive officer Adar Poonawala, the SII is the worldâs largest vaccine maker by volume, and has led in producing the lower-cost AstraZeneca coronavirus shot. The institute makes 60-70 million doses a month, and is aiming for 100 million doses by July.
Johnsonâs Downing Street office said the £240 million ($334 million) project would include a sales office, âclinical trials, research and development and possibly manufacturing of vaccinesâ.
By Reynald Castaneda 27 Apr 2021 (Last Updated April 27th, 2021 09:43)
Serum Institute of India has provided the three-month data of its Phase II/III trial investigating its Covid-19 vaccine Covishield (SII-ChAdOx1 nCoV-19) to India’s Central Drugs Standard Control Organisation (CDSCO), a spokesperson said.
The first cohort of 400 participants are in the trial’s immunogenicity group, where 300 volunteers received Covishield, and the other 100 volunteers received Vaxzevria. Credits: LookerStudio/Shutterstock.com.
Share Article
Serum Institute of India has provided the three-month data of its Phase II/III trial investigating its Covid-19 vaccine Covishield (SII-ChAdOx1 nCoV-19) to India’s Central Drugs Standard Control Organisation (CDSCO), a spokesperson said. The data pertains to Covishield immunogenicity compared with University of Oxford/AstraZeneca’s Vaxzevria (AZD1222) and Covish
Send The government has finally given the green signal to vaccinate all individuals over 18 years of age, from May 1 onward.
File photo
Chennai:
The development comes on the back of India reporting over 2.59 lakh new cases on Tuesday, and 1,761 deaths over the past 24 hours, setting grim new benchmarks in single-day spikes since the beginning of the pandemic. The Centreâs plan to liberalise its vaccination drive has come as a respite of sorts for citizens as states, private hospitals, as well as industrial establishments and corporates, will now be able to directly procure the vaccine doses from the manufacturers.
According to experts, the decision to carry out universal vaccination will lead to significant improvements in the availability of vaccines by July â buoyed by the ramping of production in domestic facilities as well as the arrival of foreign vaccines. NITI Aayog member Dr. Vinod Paul had remarked that international manufactu
RDIF awaiting SEC recommendation for Sputnik approval in India daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.